Accessibility Menu
Polaryx Therapeutics logo

Polaryx Therapeutics

(NASDAQ) PLYX

Current Price$2.28
Market Cap$115.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-93%
5 YearN/A
1 YearN/A
1 Month+1%
Polaryx Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.312026-07-16
Polaryx Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.94%USD 2.432026-07-09
1 month+0.87%USD 2.292026-06-16
3 month-62.25%USD 6.122026-04-17
Since inception-93.4%USD 35.002026-02-02

Polaryx Therapeutics Financials at a Glance

Market Cap

$115.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$6.48M

EPS (TTM)

-$0.14

P/E Ratio

-16.87

Dividend

$0.00

Beta (Volatility)

0.59 (Low)

Price

$2.28

Volume

58,012.801

Open

$2.22

Previous Close

$2.28

Daily Range

$2.20 - $2.34

52-Week Range

$2.01 - $48.91

Estimated Earnings Date

Aug 13, 2026

PLYX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Polaryx Therapeutics

Polaryx develops medicines for rare childhood brain diseases. Its treatments aim to slow disease progression and improve daily life. These therapies target children with severe, inherited neurological disorders.

Lab Bench to Bedside: What Polaryx Makes

  • PLX-200 (gemfibrozil): Oral drug for rare brain diseases in children; no revenue contribution (pre-commercial).
  • PLX-300 (cinnamic acid): Plant-derived oral therapy in early testing for rare genetic disorders; no revenue yet.
  • PLX-100: Combination oral therapy for late infantile neuronal ceroid lipofuscinosis (LINCL); preclinical stage, no sales.
  • PLX-400: Intranasal gene therapy for rare childhood brain diseases; preclinical, not yet generating revenue.

Growing Pains and Gains: Expansion Moves

  • Entered service agreement with Mstone Partners Healthcare Limited in 2021 for operational support and biotech expertise.
  • Submitted IND for PLX-200 Phase 2 trial in August 2025; FDA cleared trial in October 2025.
  • Expanded pipeline with PLX-300, PLX-100, and PLX-400 in 2025, targeting more rare diseases.
  • Secured multiple orphan drug and fast track designations for lead therapies by 2025.
  • Filed new patents in the US and internationally, extending protection into the 2040s.

Why Polaryx Is a Bit Different

Polaryx combines small molecule drugs and gene therapies for rare diseases. It uses repurposed medicines to speed up development and reduce risk. The company focuses on oral solutions for children, aiming for easier dosing and better compliance.

Five Things You Need to Know

  • Revenue was $0 in 2025 and 2024; company is pre-commercial.
  • Net loss was $9.0 million in 2025, down from $30.4 million in 2024.
  • Research and development expenses rose 124.8% to $6.3 million in 2025.
  • Cash position was $5.1 million as of December 31, 2025.
  • Company has no debt and 11 employees as of February 2026.

Bottom Line

Polaryx remains focused on developing treatments for rare childhood brain diseases. The company faces ongoing losses but continues to expand its pipeline and intellectual property.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

11

CEO

Alex Yang

Website

www.polaryx.com

Headquarters

Paramus, NJ 07652, US

PLYX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-166.07%

Return on Capital

-171.33%

Return on Assets

-184.95%

Earnings Yield

-5.93%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$115.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

49.85M

Volume

58.01K

Avg. Volume

216.47K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$4.73M

EBITDA

-$6.48M

Operating Cash Flow

-$3.95M

Capital Expenditure

$0.00

Free Cash Flow

-$3.95M

Cash & ST Invst.

$3.08M

Total Debt

$0.00

Polaryx Therapeutics Performance Analysis

Polaryx Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Polaryx Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Polaryx Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -0.08N/A
20242024-12-31USD -0.64703.5%
20252025-12-31USD -0.19-70.4%
Polaryx Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3080.1%
Q32025-09-30-43.4%
Q42025-12-31-315.8%
Q12026-03-31-70.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$115.14MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.47M

N/A

Employees

11

N/A

Net Income

-$2.54M

+49.6%

EBITDA

-$2.54M

+49.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$3.08M

-26.0%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.85%

N/A

Return on Invested Capital

-1.90%

N/A

Free Cash Flow

-$1.49M

N/A

Operating Cash Flow

-$1.49M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANTXAN2 Therapeutics, Inc.
$4.68+0.21%
KLRSKalaris Therapeutics Inc
$4.38-4.99%
KZRKezar Life Sciences, Inc.
$7.29+0.00%
NXTCNextCure, Inc.
$5.99-2.92%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$14.98-0.04%
INTCIntel
$95.04-0.02%
NOKNokia
$10.12-0.03%
PATHUiPath
$12.15+0.01%

Questions About PLYX

What is the current price of Polaryx Therapeutics?

Polaryx Therapeutics is trading at $2.28 per share.

What is the 52-week range for Polaryx Therapeutics?

Over the past 52 weeks, Polaryx Therapeutics has traded between $2.01 and $48.91.

How much debt does Polaryx Therapeutics have?

As of the most recent reporting period, Polaryx Therapeutics reported total debt of $0.00.

How much cash does Polaryx Therapeutics have on hand?

Polaryx Therapeutics reported $3.08M in cash and cash equivalents in its most recent financial results.

What is Polaryx Therapeutics’s dividend yield?

Polaryx Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services